Evidence map›Paper›PMID 37710139›Full record

Trial reportAnnals of surgical oncology2023

Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer.

Rosemary N Senguttuvan, Nicole Lugo Santiago, Ernest S Han, Byrne Lee, Stephen Lee, Wei-Chien Lin, Mehdi Kebria, Amy Hakim, Jeff F Lin, Mark T Wakabayashi and 13 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Rosemary N SenguttuvanDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Nicole Lugo SantiagoDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Ernest S HanDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Byrne LeeDepartment of Surgery, Stanford, Stanford, CA, USA.
Stephen LeeDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Wei-Chien LinDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Mehdi KebriaDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Amy HakimDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Jeff F LinDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Mark T WakabayashiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Nora RuelBiostatistics Core, City of Hope BRI, Duarte, CA, USA.
Raechelle TinsleyClinical Trials Office, COH, Duarte, CA, USA.
Melissa EngClinical Trials Office, COH, Duarte, CA, USA.
Daphne B StewartDepartment of Medical Oncology, COH, Duarte, CA, USA.
Edward W WangDepartment of Medical Oncology, COH, Duarte, CA, USA.
Benjamin I PazDivision of Surgical Oncology, Department of Surgery, COH, Duarte, CA, USA.
Xiwei WuIntegrative Genomics Core, City of Hope Beckman Research Institute (BRI), Duarte, CA, USA.
Hyejin ChoIntegrative Genomics Core, City of Hope Beckman Research Institute (BRI), Duarte, CA, USA.
Winnie S LiangTranslational Genomics Research Institute, Phoenix, AZ, USA.
Lorna Rodriguez-RodriguezDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA.
Mihaela C CristeaDepartment of Surgery, Stanford, Stanford, CA, USA.
Mustafa RaoofRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Thanh H DellingerDivision of Gynecologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center (COH), Duarte, CA, USA. tdellinger@coh.org.
City of Hope · USCity Of Hope National Medical Center · USRegeneron (United States) · USStanford Medicine · USBeckman Research InstituteTranslational Genomics Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin confers a survival benefit in epithelial ovarian cancer (EOC) but is associated with renal toxicity. Sodium thiosulfate (ST) is used for nephroprotection for HIPEC with cisplatin, but standard HIPEC practices vary.

methodsA prospective, nonrandomized, clinical trial evaluated safety outcomes of HIPEC with cisplatin 75 mg/m

resultsForty patients had HIPEC at the time of interval or secondary CRS. Renal toxicities in the nST group were 33% any grade AE and 9% grade 3 AEs. The ST group demonstrated no renal AEs. Median postoperative Cr in the nST group was 1.1 mg/dL and 0.5 mg/dL in the ST group (p = 0.0001). Median change in Cr from preoperative to postoperative levels were + 53% (nST) compared with - 9.6% (ST) (p = 0.003). PFS did not differ between the ST and nST groups in primary or recurrent EOC patients. Renal AEs were associated with downregulation of metabolic pathways and upregulation of immune pathways.

conclusionsST significantly reduces acute renal toxicity associated with HIPEC with cisplatin in ovarian cancer patients. As nephrotoxicity is high in HIPEC with cisplatin, nephroprotective agents should be considered.

Indexed as

Antineoplastic AgentsHyperthermia, InducedOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialCisplatinCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansHyperthermic Intraperitoneal ChemotherapyNeoplasm Recurrence, LocalProspective StudiesThiosulfatesAntineoplastic AgentsCisplatinsodium thiosulfateThiosulfates

Identifiers

PMID37710139
PMCPMC10625947
OpenAlexW4386739126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.